Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:lamivudine
|
| gptkbp:approvalYear |
1998
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AF05
|
| gptkbp:brand |
gptkb:lamivudine
|
| gptkbp:contraindication |
hypersensitivity to lamivudine
|
| gptkbp:drugClass |
gptkb:protease_inhibitor
|
| gptkbp:form |
gptkb:tablet
oral solution |
| gptkbp:indication |
hepatitis B virus infection
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue headache |
| gptkbp:usedFor |
chronic hepatitis B
|
| gptkbp:bfsParent |
gptkb:lamivudine
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epivir-HBV
|